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To examine the course, clinical correlates,
and relationship between cognitive status and psycho-
pathological features in patients with probable Alzheimer’s








Patients were recruited at three sites: 91 pa-
tients at Columbia Medical Center, 84 at Johns Hopkins
















sion, hallucinations, and delusions were evaluated at 6-
month intervals using the Columbia Scale for Psychopa-
thology in Alzheimer’s Disease. Descriptive analyses were
used to provide estimates of prevalence and course of psy-
chopathological features. General estimating equations de-
termined the odds of having any of the four psychopatho-
logical behaviors as a function of cognitive status. Markov
analyses provided 6-month transition probabilities for
psychopathological behaviors given patients’ cognitive sta-





For wandering/agitation, prevalence (39–57%)
and persistence increased as a function of time and decre-
ment in cognitive status. Physical aggression was less prev-
alent (6–22%) and increased as a function of cognitive de-
cline but tended to persist only in the more severely
impaired patients. Delusions (34–49%) reached a peak at
the second year and then declined. The odds of delusions
were maximal with intermediate decline but remained per-
sistent regardless of cognitive status. Hallucinations, de-
spite some fluctuations, were relatively stable during the





wandering/agitation and delusions, in AD were common
throughout the disease course. The natural history and
persistence of the four psychopathological features varied.
These findings provide important information to clinicians
and caregivers regarding the course, predictability, and
possible treatment of psychopathological behaviors in pa-
tients with probable AD. 
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sychopathological features such as delusions and hal-
lucinations are integral elements of Alzheimer’s disease
(AD) and present significant problems for family members




 Estimates of the















 These estimates vary because of different methods
by which delusions and hallucinations were diagnosed and









 are not sensitive to changes in the prev-
alence of psychotic symptoms as a function of disease
progression. There have been few longitudinal studies con-
cerning the course and prevalence of psychopathological
behaviors in AD. The authors previously reported on the
course of psychopathological features including delusions
and hallucinations in a prospective sample of patients with




Evidence for the relationship between psychotic symp-
toms, the severity of cognitive deficits, and the rate of cog-
nitive decline in AD has been inconsistent. Several studies
have demonstrated that the presence of psychotic symp-
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 Furthermore, studies ex-
amining delusions and hallucinations separately appear to
be inconsistent as to whether accelerated cognitive decline








Wandering occurs in up to 65% of patients in nursing




 and in approxi-




 Agitation has been













that the prevalence of wandering or agitation ranged from
38% to 62% during a 3-year follow-up. Also, wandering









Estimates of the prevalence of physical aggression in




 but reach 30% in a clinical









showed that the prevalence of physical aggression ranged
from 6.4% to 20.5% over a 3-year period. Although phys-





 evidence for its relationship to cognitive
status has been examined in only a few studies, yielding
mixed results. Physical aggression was related to greater









The present study examined the course, clinical corre-
lates, and relationship to decrements in cognitive status of
psychopathological behaviors in AD using the same pro-





 Specifically, the goal of this investigation was
threefold: first, to evaluate the prevalence and course of
delusions, hallucinations, wandering/agitation, and physi-
cal aggression over a 5-year period in patients with proba-
ble AD; second, to determine the odds of presenting with
behavioral disturbances as a function of cognitive status;
and third, to examine whether psychopathological distur-
bances persist over time and whether the degree of persis-
tence is related to cognitive status. To the authors’ knowl-
edge, this is the first study that provides such prospective
data for AD patients followed from mild to severe stages
of the disease.
Information regarding the course and predictability of
psychopathological behaviors in AD is of significant value
and importance to clinicians and caregivers of demented
patients. Furthermore, pharmacological treatment of psy-





 Hence, knowledge regarding the course, persistence,
and relationship to disease stage of specific psychopathologi-







Two hundred thirty-six patients, enrolled in the Predictors
study, participated in the present investigation. All pa-




 At entry into
the study, patients were required to have relatively mild
dementia, which was operationalized as modified Mini-
Mental State Examination (mMMSE) score of 30 (equiva-
lent to 16 on the Folstein MMSE). Patients were recruited
at three sites: 91 patients at Columbia Medical Center, 84
at Johns Hopkins School of Medicine, and 61 at Massa-
chusetts General Hospital. At the Columbia site, patients
were recruited from the Memory Disorder Center and
from doctors’ private offices through the Alzheimer’s Dis-
ease Research Center. Each consecutive patient who met
the inclusion/exclusion criteria of the study was included,
with the exception of those who did not consent to partic-
ipate or who lived too far away and were unable to return
to the hospital for regular follow-up. At the Johns Hop-
kins site, patients were recruited from the Dementia Re-
search Center and from private physicians. For the Massa-
chusetts General Hospital site, patients were recruited from
the Geriatric Neurobehavioral Center, an outpatient ser-
vice. In addition, 14 patients were recruited from a long-
term care facility, and eight patients also entered a physo-
stigmine study.
The inclusion/exclusion criteria and evaluation proce-





 With respect to psychiatric history, exclu-
sion criteria included a history of schizophrenia or schizo-
affective disorder, electroconvulsive therapy within the
preceding 2 years or a history of 10 or more electroconvul-
sive treatments in any one course, alcohol or drug depen-
dence during the preceding 5 years, primary affective dis-
order within 1 year before onset of dementia, and evidence
of other causes of dementia.
In the Predictors study, patients are evaluated every 6
months. The total number of patients followed from the
initial evaluation through the fifth year was 236, 205,
170, 154, 125, and 102, respectively. Of the 134 patients
lost during the 5-year follow-up, 118 died. Reasons for
loss of contract with the remaining 16 patients (6.7% of
the entire sample) included refusal to participate, reloca-
tion, and medical condition that did not allow for contin-




 standard deviation of





cating that, on average, patients have been followed for
approximately 3.5 years.
Patients’ mental status, dependence, and daily func-
tional competence were evaluated as a part of a neurologi-
















Psychopathological behaviors were assessed using the Co-





 The CUSPAD is a short semistruc-
tured rating scale that a clinician or research technician
can administer to an informant. The frame of inquiry is
the month before examination. Most items are scored di-
chotomously (i.e., symptom is present or absent). Psycho-




Interrater reliability for the major symptom categories was

















Correlations between major symptom categories were low
and statistically insignificant, indicating good divergent
validity. The CUSPAD was developed primarily to exam-
 JAGS JULY 2003–VOL. 51, NO. 7
 




ine phenomenological features, and most items lack quan-
titative rating of severity. Consequently, partial response
to treatment and fluctuation over time in item severity are
not detected with this instrument.
A trained research technician administered the
CUSPAD to an informant at the initial evaluation and at
subsequent 6-month intervals. Four dichotomous CUSPAD
categories—delusion (paranoid, misidentification, somatic,
abandonment), hallucination (visual, auditory, tactile, ol-
factory), wandering/agitation (i.e., restlessness or increased
motor activities), and physical aggression (including threat-
ening behavior)—were used for statistical analyses. The
presence of any symptom within a category led to a posi-





broad definition of a delusion (i.e., the patient does not ac-
cept the caregiver’s correction for the false belief) and the
presence of a vague or clear hallucination were used to de-









 Modifications to the original MMSE include





additional calculation items, recall of the current and four
previous presidents of the United States, confrontation





additional sentence to repeat, and one additional figure to
copy. The mMMSE has a maximum of 57 points, with
lower scores indicating poorer cognitive function. The









The percentage of patients per year experiencing delu-
sions, hallucinations, wandering/agitation, and physical
aggression was reported for a 5-year period and delineated
in relation to mean mMMSE scores. The prevalence rates,
based on all available patient visits, were compared with
those obtained for a subset of 48 patients who had com-
pleted all 6-month-interval evaluations during the 5-year
follow-up. This was done to assure that changes in yearly
prevalence rates for the entire sample did not reflect attri-
tion, missed appointments, and death.
The specific nature of the relation between cognitive
function and the prevalence of psychopathological behav-
iors was addressed in the general estimating equation




GEEs were used to calculate the odds of having each of the
psychopathological behaviors as a function of cognitive




 236) with all available
patient visits. This statistical method takes into account
the multiple visits per patient as well as the likelihood that
an individual’s characteristics correlate with each other
over time. The repeated measures per patients (up to 23 6-
month visits) are treated as a cluster. A second advantage
of GEE is that it takes into account the status or changing
value of each covariate at each visit. In the current GEE
model, five mMMSE percentile groups (0–20%ile, 21–
40%ile, 41–60%ile, 61–80%ile, 81–100%ile) served as
the categorical independent variable. Patients’ mMMSE
group membership was determined for each available 6-
month visit based on their mMMSE scores. The top per-
centile mMMSE group served as a reference group against
which the four other mMMSE percentile groups were
compared. The presence or absence of delusions, halluci-
nations, wandering/agitation, and physical aggression
served as the dichotomous dependent variable. Analyses
controlled for age, education, and sex.
Additional GEE models for delusions and hallucina-
tions controlled for the effect of psychotropic medications




Markov analyses were used to evaluate 6-month-interval
transition probabilities of psychopathological behaviors
during the 5-year follow-up. Only the 48 patients who had
completed all 6-month visits during the 5-year follow-up
were included. Patients were assigned at each 6-month
evaluation to one of five mMMSE percentile groups (0–
20%ile, 21–40%ile, 41–60%ile, 61–80%ile, 81–100%ile).
In the current model, mMMSE status and the presence or
absence of psychopathological behaviors at the preceding
6-month visit served as independent variables used to de-
termine the transition probabilities to the specified out-
come (i.e., maintaining or developing psychopathological




Of the 236 participants, 59% were female; the majority of




 standard deviation age and














cating an overall mild level of cognitive impairment. The
modal dependence level at baseline was 2 (54% of the pa-
tients), suggesting that, initially, most patients required
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The percentage of patients per year experiencing wandering/
agitation, physical aggression, hallucinations, and delu-
sions during the 5-year follow-up is presented in Figure 1.
These findings are presented in relation to yearly mean
mMMSE scores.
Inspection of Figure 1 reveals that the symptoms of
wandering/agitation and physical aggression tended to in-
crease as a function of time and disease progression. The
prevalence of hallucinations tended to increase slightly
over the 5-year period. For delusions, maximal prevalence
appeared to occur in the second year, with a subsequent de-
cline. Only seven patients were determined to be mute at the
end of the 5-year follow-up, suggesting that the decline in
the prevalence of delusions (after a peak) was not solely due
to patients’ inability to communicate delusional experiences.
The percentage of patients experiencing psychopatho-
logical behaviors also was calculated using the subset of
48 patients who had completed all 6-month visits during
the 5-year follow-up. This was initiated to assure that
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tions in the number of patients evaluated each year. In-
deed, the two analyses were similar in terms of the preva-
lence and changes over time in the prevalence rates of the
four psychopathological behaviors examined.
It appears that decline in mMMSE scores was associ-
ated with an increase in the percentage of patients experi-
encing any one of the four psychopathological behaviors
examined, but in these descriptive analyses, mMMSE data
were delineated as a sample mean per year, limiting inferences
regarding the association between the severity of mMMSE de-
cline and changes in the prevalence of psychopathological be-
haviors. Therefore, the odds of presenting with psychopatho-
logical symptoms, as a function of cognitive status, were




The mMMSE group status, for all available 6-month vis-
its, served as the categorical independent variable. The
highest percentile group (81–100%ile) constituted a refer-
ence group against which the four lower mMMSE percen-
tile groups were compared. The presence or absence of
each psychopathological category for each 6-month visit
served as the dichotomous dependent variable. Table 1
presents significance level and odds ratio (OR) (i.e., associ-
ated risk) of exhibiting psychopathological behaviors as a
function of cognitive status.
Inspection of Table 1 revealed that the odds of exhibit-
ing wandering/agitation and physical aggression increased
as a function of decrements in cognitive status. Member-
ship in the 61 to 80 percentile, 41 to 60 percentile, 21 to
40 percentile, and 0 to 20 percentile mMMSE groups was
associated with a 1.5, 2.0, 3.3, and 4.2-fold increase, re-
spectively, in the odds of having wandering/agitation, rela-
tive to the reference group. For physical aggression, mem-
bership in the 61 to 80 percentile, 41 to 60 percentile, 21
to 40 percentile, and 0 to 20 percentile mMMSE groups
was associated with a 3.5-, 3.1-, 3.6-, and 9.0-fold in-
crease, respectively, in the odds of having such behavior.
Lower mMMSE percentile group status also was associ-
ated with higher odds (range of 2- to 3.3-fold relative to
the reference group) of having hallucinations. The odds of
having delusions increased by 1.4-, 2.3-, and 2.4-fold in
the 61 to 80 percentile, 41 to 60 percentile, and 21 to 40
percentile groups, respectively, compared with the refer-
Figure 1. Percentage of patients deemed to present with (A) wandering/agitation, (B) physical aggression, (C) hallucination, and (D)
delusions during the initial evaluation and 5-year follow-up. mMMSE  Modified Mini-Mental State Examination.
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ence group. However, the odds of having delusions in the
0 to 20 percentile of the mMMSE group were not signifi-
cantly different from the odds reported for the reference
group. The results of the GEE analyses appeared consis-
tent with the descriptive data described earlier regarding
the course of each of the four psychopathological catego-
ries and its relationship with cognitive function.
The effect of psychotropic medications on psychotic
symptoms and cognition was addressed as well. GEE anal-
yses for delusions and hallucination were repeated under
two different exclusionary conditions. First, only visits
during which patients were on psychotropic medications
were excluded. Second, patients were excluded if psychotro-
pic medications were used at any point during the course of
their follow-up. Compared with the initial models, the as-





Markov analysis was used to determine 6-month transi-
tional probabilities of psychopathological behaviors. Ta-
ble 2 presents transition probabilities for each psycho-
pathological behavior as a function of mMMSE status and
whether the behavior was present in the preceding visit.
Transition probabilities range from 0 to 1. For exam-
ple, transition probability of 0.20 for “new onset” of
wandering/agitation in the 81 to 100 percentile mMMSE
group, indicates that 20% of patients not reported to ex-





 1), manifested such behavior at the next 6-month
visit (n). A transition probability of 0.54 for “persistent”
status of wandering/agitation in the 81 to 100 percentile
mMMSE group indicates that 54% of the patients re-
ported to exhibit wandering/agitation in the preceding 6-




 1) manifested such behavior at the next
6-month visit (n).
Table 2 reveals that mMMSE status and the presence
of psychopathological behaviors at one 6-month visit were
significant predictors of transitional probabilities at the
next 6-month visit.
For wandering/agitation, transition probabilities in-
creased from 0.20 in the 81 to 100 percentile mMMSE
group to 0.48 in the 0 to 20 percentile mMMSE group
when this behavior was not present in the preceding visit.
The transition probabilities for these high and low
mMMSE percentile groups rose to 0.54 and 0.80, respec-
tively, when this behavior was present in the preceding visit.
Transitional probabilities for physical aggression also in-
creased as a function of decrements in cognitive status
(0.05 and 0.26 in the 81–100%ile and 0–20%ile mMMSE
groups, respectively) in the absence of this behavior at the
preceding 6-month visit. When physical aggression was
present in the preceding interval, the transition probabili-
ties rose to 0.27 and 0.69 in the high and low mMMSE
percentile groups, respectively. Furthermore, it is notewor-
thy that physical aggression appeared to be persistent only
 
 















81–100 39–57 1 Reference 1 Reference 1 Reference 1 Reference
61–80 33–38 1.5 .0568 3.5 .0016 2.0 .0287 1.4 .0314






























Table 2. Markov Analysis—Transition Probabilities for Wandering/Agitation, Physical Aggression, Hallucination, and






Wandering/Agitation Physical Aggression Hallucination Delusion
Percentile New Onset Persistent New Onset Persistent New Onset Persistent New Onset Persistent 
81–100 39–57 0.20 0.54 0.05 0.27 0.03 0.14 0.18 0.76
61–80 33–38 0.24 0.59 0.04 0.20 0.12 0.42 0.17 0.75
41–60 26–32 0.35 0.72 0.04 0.22 0.07 0.30 0.20 0.78
21–40 14–25 0.49 0.81 0.18 0.59 0.15 0.50 0.23 0.82
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in the two lower mMMSE percentile groups. Six-month
transitional probabilities for hallucinations, although
tending to increase as a function of lower mMMSE per-
centile group status, appeared to fluctuate when hallucina-
tions were present or absent in the preceding 6-month in-
terval. Membership in the 81 to 100 percentile mMMSE
group was associated with the lowest transition probabili-
ties for the new onset and persistent conditions. Six-month
transition probabilities for delusions increased as a func-
tion of lower mMMSE percentile group status in the new
onset and persistent conditions but then decreased in the 0
to 20 percentile mMMSE group. Additionally, delusions




The present study examined the course and prevalence of
wandering/agitation, physical aggression, delusions, and
hallucinations in patients with probable AD over a 5-year
period. The odds of presenting these psychopathological
behaviors were examined in relation to cognitive status.
Also, 6-month transition probabilities for each psycho-
pathological behavior were determined. The current find-
ings replicate and extend previously published data for the








demonstrating that behavioral disturbances are common
in AD. Specifically, wandering/agitation increased from a
baseline prevalence rate of 39% to a peak of 57%. Physi-
cal aggression, although not as prevalent, also increased as
a function of the disease course and peaked at 22%. The
prevalence of hallucinations remained relatively stable
during the 5-year follow-up, ranging from 8% to 17%.
Delusions increased during the first and second years,
reaching a peak of 49%, with a subsequent drop to 34%
at the end of the 5-year follow-up. These results may ex-
plain some of the reported variability of psychopathologi-
cal behaviors in AD, because the range of prevalence rates
for these four behavioral disturbances varied substantially
as a function of time and disease course. Despite the note-
worthy increase in the prevalence of wandering/agitation,
physical aggression, hallucinations, and delusions as a
function of the disease course, these behavioral distur-





 they appeared throughout the
5-year follow-up. It should be emphasized that changes in
prevalence of the different psychopathological features
over the course of follow-up are not likely to reflect fluctu-
ations in the number of patients evaluated each year. In-
deed, such prevalence rates were similar in a subset of pa-
tients who were present at all 6-month evaluations.
The findings of this investigation provided strong sup-
port to previous research in favor of the association be-














 GEE analyses revealed that the odds of experi-
encing these psychopathological disturbances increased
significantly as a function of declining cognitive status. A
conservative approach excluding all patients prescribed
psychotropic medications did not attenuate the relation
between psychotic symptoms and cognitive status. Fur-
thermore, with the exception of four participants, patients
who were prescribed cholinesterase inhibitors at some
point during the follow-up also were prescribed psycho-
tropic medications and consequently were excluded from
these analyses as well.
In the present study, the mMMSE served as the sole
measure of cognition, limiting the extent and specificity of
the conclusions regarding the association between cogni-
tive function and psychopathological features in AD. Of
interest is whether decline in specific cognitive domains
can provide additional information beyond that available
from the mMMSE, with respect to the risk of experiencing





 revealed that decline in measures of atten-
tion, construction, and fluency, which are considered sen-
sitive to frontal lobe dysfunction, were related to an in-
crease in the risk of developing psychosis in patients with
probable AD. These results, in concert with the strong as-
sociation between cognitive dysfunction and psychopatho-
logical features documented in the presented study, may
be viewed as supportive evidence of the hypofrontality
model of psychosis in AD. This model argues that patients
with probable AD who experience a disproportionate dys-
function of frontal circuitry are at greater risk of develop-
ing psychosis. Physical aggression and wandering/agita-
tion may be considered symptoms of compromised ability
to inhibit responses, a cognitive behavioral deficit that has
been attributed to frontal dysfunction as well. Taken to-
gether, the evolution and progression of psychopathological
features in AD may be related, at least to some extent, to
damage in frontal regions.




revealing that psychopathological behaviors were not only
prevalent in AD but also persistent. That is, patients who
presented with behavior disturbances at one 6-month eval-
uation were more likely to exhibit the same disturbance at
the following 6-month evaluation relative to those patients
who did not present with the same behavioral disturbance
at the previous evaluation. Nevertheless, the degree of per-
sistence of symptoms differed among the four psycho-
pathological behaviors and also varied as a function of
cognitive status. The transition probabilities for wandering/
agitation revealed that this behavior was persistent in all
mMMSE percentile groups but that the level of persistence
increased as cognitive status decreased. Physical aggres-
sion appeared to be persistent only in the two lower
mMMSE percentile groups. Hallucinations were not per-
sistent in the 81 to 100 percentile mMMSE group but
appeared moderately persistent (transition probabilities
ranged from 0.30 to 0.50) in the other mMMSE percentile
groups. Delusions were persistent irrespective of cognitive
status, although a reduction in transition probabilities was
noted in the 0 to 20 percentile mMMSE group.
Data concerning the persistence of psychopathological
features have some limitations in that Markov analyses
did not control for psychotropic medications, because of
the small number of patients (n  48). Furthermore, the
CUSPAD was developed primarily to examine phenome-
nological features, and most items lack quantitative rating
of severity. Hence, this instrument would have missed re-
duction in symptoms severity due to pharmacological in-
tervention without complete remission.
There were some noteworthy differences among the
four psychopathological behaviors in terms of their preva-
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lence and relation to cognitive status. Wandering/agitation
and physical aggression, despite differences in prevalence
rates, tended to increase as a function of disease course
and decrements in cognitive function. The dramatic in-
crease in the odds of exhibiting physical aggression in the
0 to 20 percentile mMMSE group relative to the reference
group (9.0-fold) and the persistence of this behavior (tran-
sitional probabilities  0.69) in this group is noteworthy.
It appears that patients with severe cognitive dysfunction
who were physically aggressive in the past are especially
prone to exhibit this behavior again. Hallucinations, despite
some fluctuations, remained relatively stable across the du-
ration of the follow-up. Nonetheless, the odds of having
hallucinations increased as cognitive status decreased.
The prevalence of delusions peaked at the end of the
second year, followed by a subsequent drop. An examina-
tion of descriptive and GEE analyses suggests that the rela-
tionship between the prevalence of delusions and cognitive
status is not linear. The odds of having delusions increased
as a function of cognitive dysfunction but then dropped
when cognitive status reached a bottom level. The reason
for this phenomenon is not clear. As indicated by these
data, inability to communicate delusional experiences does
not appear to provide a satisfactory explanation. It can be
speculated that delusions require a relatively complex cog-
nitive substrate not available when cognitive function is
most severely compromised. Nonetheless, the prevalence
of delusions remained at 34% at the end of the 5-year pe-
riod. Future research may provide insight into whether the
content of delusions is simplified as the disease progresses.
Hence, the reduction in the prevalence of delusions over
time may be explained if complex delusions are not experi-
enced at the end stages of AD.
The longitudinal design of this study has significant
advantages over cross-sectional studies when evaluating
the manifestation and progression of psychopathological
features over time and in relation to cognitive status in AD.
Specifically, when assessed longitudinally, the increase in
symptoms can be attributed directly to disease progress
and the severity of cognitive dysfunction. In contrast, find-
ings from cross-sectional studies cannot be used to make
inferences regarding such disease processes. (For a recent
review concerning the limitations of cross-sectional studies
with respect to disease processes see Kraemer et al.53) Fur-
thermore, the findings of the present study afford valuable
information to clinicians and caregivers of demented pa-
tients regarding the course and predictability of psycho-
pathological behaviors in AD. For example, the high fre-
quency and persistent nature of wandering/agitation and
delusions indirectly suggests that treatment for these
symptoms may need to be prolonged. Also, physical ag-
gression, relatively infrequent early in the disease, appears
to persist only in late phases. This suggests that once treat-
ment for this behavior begins it may need to be adminis-
tered continuously. Finally, the findings of this study were
based on a relatively large prospective sample, allowing
for conclusions that are likely applicable to many AD pa-
tients. Nevertheless, the Caucasian predominance and rel-
atively high education level in this sample may limit the
generalizability of the findings to patients of different eth-
nic origins with less education.
In summary, this prospective study demonstrated that
psychopathological behaviors, particularly wandering/
agitation and delusions, in AD were common. The odds of
presenting with any one of the four psychopathological
behaviors increased significantly as a function of decline in
cognitive status. Finally, transition probabilities showed
that psychopathological behaviors were persistent but that
the degree of persistence varied as a function of cognitive
status and type of behavior.
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